Updated:
AI that flags lung CT for referral: who acts on the flag?
FDA's new device type for fibrotic lung disease referral software, and the workflow questions it raises for hospital admin and nursing teams.
Some AI tools do not make a diagnosis. They point out a case that may need a closer look and send it down a referral pathway. On October 30, 2026, the FDA published an order creating a device type for this kind of software in lung imaging. The rule itself is about what manufacturers must show. But the way the FDA describes the risks is a useful checklist for hospitals deciding how such a flag fits into daily work. This post is general information, not legal advice.
What the FDA order says
The Federal Register order adds 21 CFR 892.2085, “Radiology software for referral of findings related to fibrotic lung disease,” as a class II device with special controls. The order is effective October 30, 2026; the classification itself was applicable from January 12, 2024, when the FDA granted the original De Novo request.
According to the full text, the device is a prescription image-processing tool. It analyzes CT images to suggest disease or a finding suggestive of disease, and its output is adjunctive information within a referral pathway that is part of the overall diagnostic assessment. In other words, it adds information; it is not the final word.
The risks the FDA lists
The order names the main risks to health:
- False positives: a flag that leads to wrong or delayed management of a patient who has a different lung disease.
- False negatives: no flag, so a patient with the disease is managed late or incorrectly.
- Misuse: running the software on the wrong patients, or on images from incompatible scanners or settings.
- Overreliance: misreading the output or leaning on it too heavily.
- Device failure: results that are missing, delayed, or wrong.
Labeling must describe the clinical context and workflow, compatible imaging hardware and protocols, performance testing results, and a warning to use the device together with other clinical and diagnostic findings.
Questions for your team before go-live
These are our suggestions, not FDA requirements. Confirm details with your radiology, compliance, and IT leads.
- Who receives the flag? Name the role that sees it, and the backup on nights and weekends.
- What happens next, and by when? A referral flag is only useful if someone schedules the follow-up. Agree who owns that step.
- Does our scanner setup match the labeling? Ask the vendor to confirm compatible hardware and protocols in writing.
- What if the software is down? Plan how staff will know results are missing or late.
Key takeaways
- The FDA created 21 CFR 892.2085, a class II device type for CT software that suggests fibrotic lung disease findings for referral.
- Its output is adjunctive information in a referral pathway, not a stand-alone answer.
- Listed risks include false positives and negatives, misuse on incompatible images, overreliance, and device failure.
- Before go-live, decide who receives the flag, who owns follow-up, and what to do if the tool fails.
Source: Federal Register, October 30, 2026 (FDA-2026-N-12254)
This site’s content is for general information, research, and education. It does not replace medical diagnosis or advice for any specific patient, and it is not legal advice.